These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38536646)

  • 21. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection.
    Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae.
    Falcone M; Bassetti M; Tiseo G; Giordano C; Nencini E; Russo A; Graziano E; Tagliaferri E; Leonildi A; Barnini S; Farcomeni A; Menichetti F
    Crit Care; 2020 Jan; 24(1):29. PubMed ID: 32000834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Characteristics and Associated Factors for Mortality in Patients with Carbapenem-Resistant
    Ahn JY; Ahn SM; Kim JH; Jeong SJ; Ku NS; Choi JY; Yeom JS; Song JE
    Microorganisms; 2023 Apr; 11(5):. PubMed ID: 37317095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for carbapenem-resistant K. pneumoniae bloodstream infection and predictors of mortality in Chinese paediatric patients.
    Zhang Y; Guo LY; Song WQ; Wang Y; Dong F; Liu G
    BMC Infect Dis; 2018 May; 18(1):248. PubMed ID: 29855274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective Analysis of Epidemiology, Risk Factors, and Outcomes of Health Care-Acquired Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in a Chinese Tertiary Hospital, 2010-2019.
    Li M; Yang S; Yao H; Liu Y; Du M
    Infect Dis Ther; 2023 Feb; 12(2):473-485. PubMed ID: 36520329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology and Prognosis of Intensive Care Unit-Acquired Bloodstream Infection.
    Kallel H; Houcke S; Resiere D; Roy M; Mayence C; Mathien C; Mootien J; Demar M; Hommel D; Djossou F
    Am J Trop Med Hyg; 2020 Jul; 103(1):508-514. PubMed ID: 32314689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiology, mortality and risk factors for patients with K. pneumoniae bloodstream infections: Clinical impact of carbapenem resistance in a tertiary university teaching hospital of Beijing.
    Zhang G; Zhang M; Sun F; Zhou J; Wang Y; Zhu D; Chen Z; Chen Q; Chang Q; Liu H; Chai W; Pan H
    J Infect Public Health; 2020 Nov; 13(11):1710-1714. PubMed ID: 33082112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunosuppression at ICU admission is not associated with a higher incidence of ICU-acquired bacterial bloodstream infections: the COCONUT study.
    Zebian G; Kreitmann L; Houard M; Piantoni A; Piga G; Ruffier des Aimes S; Holik B; Wallet F; Labreuche J; Nseir S
    Ann Intensive Care; 2024 Jun; 14(1):83. PubMed ID: 38837065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of Mortality-Related Risk Factors and Effective Antimicrobial Regimens for Treatment of Bloodstream Infections Caused by Carbapenem-Resistant
    Chen L; Han X; Li Y; Li M
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0069821. PubMed ID: 34228539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors associated with inappropriate empirical antimicrobial treatment in bloodstream infections. A cohort study.
    Dietl B; Boix-Palop L; Gisbert L; Mateu A; Garreta G; Xercavins M; Badía C; López-Sánchez M; Pérez J; Calbo E
    Front Pharmacol; 2023; 14():1132530. PubMed ID: 37063300
    [No Abstract]   [Full Text] [Related]  

  • 31. [Analysis of prognostic risk factors of bloodstream infection in intensive care unit patients].
    Huang Y; Gong C; Fu J; Liu X; Bi H; Wang H; Liu Y; Tang Y; Wang D
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Dec; 32(12):1440-1444. PubMed ID: 33541494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical characteristics and prognostic risk factors analysis of carbapenem-resistant organism in the department of hematology].
    Chen SZ; Xu JJ; Xiao TT; Weng YX; Chen DB; Zhang Y; Ren JH; Luo XF; Zheng ZH; Zheng XY; Chen ZZ; Hu JD; Yang T
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):563-569. PubMed ID: 34455743
    [No Abstract]   [Full Text] [Related]  

  • 33. Antibiotic strategies and clinical outcomes for patients with carbapenem-resistant Gram-negative bacterial bloodstream infection.
    Qu J; Feng C; Li H; Lv X
    Int J Antimicrob Agents; 2021 Mar; 57(3):106284. PubMed ID: 33484833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Threat of Carbapenem-Resistant Gram-Negative Bacteria in Patients with Hematological Malignancies: Unignorable Respiratory Non-Fermentative Bacteria-Derived Bloodstream Infections.
    Lu L; Xu C; Tang Y; Wang L; Cheng Q; Chen X; Zhang J; Li Y; Xiao H; Li X
    Infect Drug Resist; 2022; 15():2901-2914. PubMed ID: 35693849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cefiderocol Versus Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii Complex Bloodstream Infections: A Retrospective, Propensity-Score Adjusted, Monocentric Cohort Study.
    Bavaro DF; Papagni R; Belati A; Diella L; De Luca A; Brindicci G; De Gennaro N; Di Gennaro F; Romanelli F; Stolfa S; Ronga L; Mosca A; Pomarico F; Dell'Aera M; Stufano M; Dalfino L; Grasso S; Saracino A
    Infect Dis Ther; 2023 Aug; 12(8):2147-2163. PubMed ID: 37653122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Novel Nomogram for Predicting Risk Factors and Outcomes in Bloodstream Infections Caused by
    Chen Y; Ying S; Jiang L; Dong S; Dai J; Jin X; Yu W; Qiu Y
    Infect Drug Resist; 2022; 15():1317-1328. PubMed ID: 35378894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbapenem-resistant
    Ruvinsky S; Voto C; Roel M; Deschutter V; Ferraro D; Aquino N; Reijtman V; Galvan ME; Motto E; García M; Sarkis C; Bologna R
    Front Public Health; 2022; 10():983174. PubMed ID: 36091556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk Factors for a Hospital-Acquired Carbapenem-Resistant
    Cao Z; Yue C; Kong Q; Liu Y; Li J
    Infect Drug Resist; 2022; 15():641-654. PubMed ID: 35241916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for carbapenem-resistant
    Cogliati Dezza F; Covino S; Petrucci F; Sacco F; Viscido A; Gavaruzzi F; Ceccarelli G; Raponi G; Borrazzo C; Alessandri F; Mastroianni CM; Venditti M; Oliva A
    JAC Antimicrob Resist; 2023 Aug; 5(4):dlad096. PubMed ID: 37577156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Appropriate antibiotic therapy is a predictor of outcome in patients with Stenotrophomonas maltophilia blood stream infection in the intensive care unit.
    Lai JJ; Siu LK; Chang FY; Lin JC; Yu CM; Wu RX; Wang CH
    J Microbiol Immunol Infect; 2023 Jun; 56(3):624-633. PubMed ID: 36948945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.